





ROCHE-POSAY
ROCHE-POSAY Toleriane Rosaliac AR SPF30 Cream
Product from:
50 mlPreussen
€24.90 €498.00 /l
Delivery within 60 minutes
AI Summary
- Description
- Composition
- Similar products
- More from this brand
- Recipes
You're reading an Auto-translation.
Product features
La Roche Posay Toleriane Rosaliac AR SPF 30: Moisturising day cream with sun protection factor 30 for sensitive and reactive skinThe non-comedogenic day cream TOLERIANE ROSALIAC AR SPF 30 protects against UV rays, which can intensify redness.
The La Roche Posay TOLERIANE ROSALIAC AR SPF 30 day cream with UVA and UVB protection protects and nourishes sensitive and redness-prone facial skin.
Skin type
sensitive skinArea of application
FaceProduct description
The TOLERIANE ROSALIAC AR SPF 30 day cream with sun protection factor from La Roche Posay protects the skin from harmful UV rays, which can intensify redness. The formula also contains Sphingobioma, which supports the function of the microbiome and, together with thermal water from La Roche-Posay, ensures protected and healthy-looking skin. Glycerin simultaneously protects the skin from drying out and provides moisture.The TOLERIANE ROSALIAC AR SPF 30 day cream is non-comedogenic and fragrance-free. Due to its ultra-light texture, the cream is quickly absorbed, leaves no shine and is ideal for sensitive and rosacea-prone skin.
Application
Apply the TOLERIANE ROSALIAC AR SPF 30 day cream from La Roche Posay to cleansed facial skin every morning and/or during the day as needed. Carefully distribute and massage the cream with sun protection factor using your fingertips. Avoid the eye area. TOLERIANE ROSALIAC AR SPF30 can also be used in combination with the previous application of TOLERIANE ROSALIAC AR intensive care.If you are staying in the sun for a longer period of time or sweating heavily, the day care can also be applied several times to maintain sun protection. The midday heat and excessive sun exposure should also be avoided.
Compatibility
sensitive skinSource: Manufacturer's information
Status: 07/2023
